Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
نویسندگان
چکیده
Division of Cardiac Surgery, St Michael’s Hospital and Toronto General Hospital, University of Toronto, Toronto, ON M5G 2CA, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada; Division of Endocrinology, St Michael’s Hospital, Toronto, Ontario, Canada; Division of Cardiology, McMaster University, Hamilton, Ontario, Canada; and Division of Cardiology, North York General Hospital, Toronto, Ontario, Canada
منابع مشابه
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
AIMS The aim of this study was to assess the effect of the angiotensin converting enzyme inhibitor perindopril on cardiovascular events in diabetic patients with coronary artery disease. METHODS AND RESULTS A total of 1502 diabetic patients with known coronary artery disease and without heart failure of 12 218 overall in the EUropean trial on Reduction Of cardiac events with Perindopril in st...
متن کاملACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
OBJECTIVES EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Our objective was to study the effect of perindopril on endothelial function and...
متن کاملThe EUROPA Trial : Design , Baseline Demography and Status of the Substudies On behalf of the EUROPA Investigators
Background: Angiotensin-converting enzyme inhibitors do reduce both mortality and morbidity in patients with left ventricular dysfunction, recent myocardial infarction and hypertension. However, the long-term effects in patients with coronary artery disease have not been established. The EUROPA study is designed to assess the longterm (3–4 years) effects of perindopril on the reduction of cardi...
متن کاملArterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trials.
Rodriguez-Granillo et al. report arterial remodelling data from the ‘PERSPECTIVE’ study, an imaging substudy of the ‘EUROPA’ study. ‘EUROPA’ is a randomized, placebocontrolled, multicentre trial, which demonstrated that the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced adverse clinical events in 12 218 patients with stable coronary artery disease (CAD). The EUROPA investigat...
متن کاملCost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
BACKGROUND The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported. OBJECTIVE To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK. METHODS Clinical and resource use data were taken from the EUROPA trial. Costs included drugs and hospitalisations. Health-related quality of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- European heart journal
دوره 26 14 شماره
صفحات -
تاریخ انتشار 2005